QuiaPEG

About

 
Board of directors
Management team
Company overview

Management Team

Mr. Marcus Bosson 

CHIEF EXECUTIVE OFFICER
Marcus Bosson, M.Sc., SSE, has a background from the venture capital industry as well as from the biotechnology industry as a founder of several successful companies. Mr. Bosson has raised approximately MUSD 100 in venture capital to companies founded by him. Mr. Bosson is currently CEO of QuiaPEG Pharmaceuctials AB, a company he co-founded in 2012.

Dr. Marek Kwiatkowski 

CHIEF SCIENTIFIC OFFICER
Dr. Kwiatkowski currently serves as Associated Professor at the Department of Bioorganic Chemistry at Uppsala University, Sweden. Dr. Kwiatkowski completed his studies in chemistry and biophysics at the Jagiellonian University, Poland and received his Ph.D. concerning RNA chemistry at the Institute for Bioorganic Chemistry at Uppsala University, Sweden, in 1984. He has worked for large international companies as well as small start-ups and most recently he worked at Department of Medical Genetics and Department of Cell and Molecular Biology at Uppsala University. Dr. Kwiatkowski is co-author of over 70 scientific papers and inventor of 28 issued patents.

 

Senior Scientific Advisors

Dr. James M. Van Alstine 

SENIOR SCIENTIFIC ADVISOR
James M. Van Alstine is acting as a Senior Scientific Advisor to QuiaPEG. Dr. Van Alstine holds a B. Sc. in Biochemistry and a Ph. D. in Experimental Pathology from the University of British Columbia in Vancouver. For many years he was a Professor at the University of Alabama in Huntsville, and a colleague of Prof. J. Milton Harris who founded Shearwater Polymers (now part of Nektar Corporation). They published many key papers on modification of proteins and surfaces with polymers such as "PEG". Dr. Van Alstine moved to Stockholm in the 1990´s and was a Professor at the Royal Institute of Technology prior to joining GE Healthcare in Uppsala in 2000. 

Over the next 14 years Jim played a senior scientific role in the development of bioseparations products, including chromatography resins for purification of PEG-modified proteins. He was also heavily involved in technology evaluation and sourcing, and the R&D to Marketing interface. In 2014 Jim started his own consulting company JMVA Biotech AB. 

He is the author of approximately 100 scientific papers, including several key reviews on PEGylation technology and is listed as inventor on over 50 national patents covering over 20 patent families. He currently reviews for a number of international scientific journals including J. Chromatography, Biotechnology and Bioengineering, and J. Colloid and Interface Science.

Dr. Bengt Sparf 

SENIOR ADVISOR, DRUG DEVELOPMENT

Bengt Sparf is acting as a Senior Advisor in pharmaceutical development to QuiaPEG. Dr. Sparf holds a Ph.D. in Biochemistry and Pharmacology from the University of Uppsala. For many years he held a number of leading positions within pharmaceutical companies. He was Director of Preclinical and Clinical Pharmacology and Pharmacokinetics at Kabi/KabiPharmacia and he was the project leader during discovery research until registration of Detrusitol™, a major global brand for the treatment of urinary incontinence. Dr. Sparf also headed the Research area of Urology and Gynecology and was a member of the management team for the Business Unit Urology within Pharmacia Corporation. Dr. Sparf currently serves as a consultant to pharmaceutical corporations within drug development and issues related to in-licensing. Dr. Sparf is listed as an inventor of Detrusitol™ and Toviaz™.

Contact
QuiaPEG Pharmaceuticals Holding AB

Virdings Allé 32 B
754 54 Uppsala
Sweden
+46 (0) 70 693 12 53
info@quiapeg.com

User terms & privacy policy
Send a message